Becker's Healthcare August 13, 2024
In 2023, more than 61% of Ozempic prescriptions went to patients with commercial health insurance, and less than 10% of all semaglutide prescriptions went to Medicaid enrollees, according to a study published Aug. 2 in JAMA Health Forum.
The researchers used data that captures 92% of prescriptions dispensed at U.S. retail pharmacies between January 2021 and December 2023.
The study analyzed monthly prescriptions for semaglutide brands Ozempic, Wegovy, and Rybelsus that were paid for through commercial insurance, Medicaid, Medicare Part D, or...
Today's Sponsors
Today's Sponsor